Omnicell shares rally 21% after reporting first-quarter profit

7 articles · Updated · MarketWatch · Apr 28

Omnicell posted a Q1 profit of $11.4 million, or 25 cents per share, reversing a $7.02 million loss last year.
Revenue rose 15% to $309.9 million, surpassing analyst expectations. The company forecasts Q2 adjusted earnings of 40–48 cents per share and full-year revenue of $1.22–$1.26 billion.
The Fort Worth-based healthcare technology provider credits improved revenue growth for its turnaround, with shares rising to $45.50 premarket. Omnicell’s performance exceeded analyst estimates, boosting investor confidence.

With a product recall just weeks ago, can Omnicell's stock rally be sustained by strong earnings alone?

Is Omnicell's growth a true turnaround or a temporary high before market challenges and new regulations hit?

Does Omnicell's current stock price fully account for the risks associated with its recent product safety issues?

Can Omnicell's technology truly solve the healthcare industry's deep-rooted medication error problem?

With new AI laws emerging in 2026, how is Omnicell ensuring its automated systems are compliant and safe?

Omnicell's vision is an 'Autonomous Pharmacy,' but how close is this AI-driven future to reality for most hospitals?